Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,655,202
  • Shares Outstanding, K 101,654
  • Annual Sales, $ 168,800 K
  • Annual Income, $ 67,970 K
  • 60-Month Beta 1.94
  • Price/Sales 16.21
  • Price/Cash Flow 34.72
  • Price/Book 5.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.11
  • Number of Estimates 7
  • High Estimate 0.01
  • Low Estimate -0.16
  • Prior Year 0.24
  • Growth Rate Est. (year over year) -145.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.51 +33.88%
on 03/18/20
37.00 -29.41%
on 03/04/20
-9.03 (-25.69%)
since 03/03/20
3-Month
19.51 +33.88%
on 03/18/20
61.29 -57.38%
on 01/08/20
-35.44 (-57.57%)
since 01/03/20
52-Week
17.30 +50.98%
on 05/02/19
73.72 -64.57%
on 11/29/19
+6.63 (+34.02%)
since 04/03/19

Most Recent Stories

More News
First Week of May 15th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options...

ARWR : 26.12 (-2.94%)
Coherus Bioscien has the Best Relative Performance in the Biotechnology Industry (CHRS , BLUE , TGTX , ARWR, AMAG )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

BLUE : 41.88 (-1.71%)
CHRS : 14.43 (-3.54%)
TGTX : 8.95 (-5.09%)
ARWR : 26.12 (-2.94%)
Arrowhead Pharma Set to Possibly Pullback After Yesterday's Rally of 23.37%

Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $20.56 to a high of $26.45. Yesterday, the shares gained 23.4%, which took the trading range above the 3-day high...

ARWR : 26.12 (-2.94%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of comScore, Inc. (NASDAQ: SCOR), Mammoth Energy Services, Inc. (NASDAQ:...

SCOR : 2.22 (-4.31%)
TUSK : 0.6097 (-11.64%)
AMC : 2.27 (+1.34%)
ARWR : 26.12 (-2.94%)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 11, 2020, the Compensation Committee of the Board of Directors...

ARWR : 26.12 (-2.94%)
Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced precautionary measures the company is taking to help protect the health and safety of its employees, partners, and the healthcare workers and...

ARWR : 26.12 (-2.94%)
58.9% Return Seen to Date on SmarTrend Arrowhead Pharma Call (ARWR)

SmarTrend identified a Downtrend for Arrowhead Pharma (NASDAQ:ARWR) on January 10th, 2020 at $58.73. In approximately 2 months, Arrowhead Pharma has returned 58.87% as of today's recent price of $24.15....

ARWR : 26.12 (-2.94%)
Arrowhead Pharma Falls 3.42% on Heavy Volume: Watch For Potential Rebound

Arrowhead Pharma (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $23.71 to a high of $26.67. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...

ARWR : 26.12 (-2.94%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Zuora, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of comScore, Inc. (NASDAQ: SCOR), Zuora, Inc. (NYSE: ZUO), AMC Entertainment Holdings,...

AC : 26.65 (-1.91%)
SCOR : 2.22 (-4.31%)
ZUO : 8.23 (-0.24%)
AMC : 2.27 (+1.34%)
ARWR : 26.12 (-2.94%)
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company's investigational RNA interference (RNAi)...

ARWR : 26.12 (-2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade ARWR with:

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

2nd Resistance Point 27.84
1st Resistance Point 26.98
Last Price 26.12
1st Support Level 25.55
2nd Support Level 24.98

See More

52-Week High 73.72
Fibonacci 61.8% 52.17
Fibonacci 50% 45.51
Fibonacci 38.2% 38.85
Last Price 26.12
52-Week Low 17.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar